ANNAPOLIS, Md. (AP) — Members of a Maryland legislative ethics panel aren’t saying whether they have decided to hold a full investigation into a delegate who was a leading architect of the state’s medical marijuana law. He is also a consultant for a company that is a finalist to grow and process the drug.
Several lawmakers on the General Assembly’s Joint Committee on Legislative Ethics declined to comment after the nearly three-hour meeting Wednesday.
Sen. James DeGrange, who is the panel’s co-chairman, told reporters after the meeting “everything is confidential.”
Del. Dan Morhaim’s role as a leading advocate for the law and his position as a consultant with Doctors Orders Maryland have raised questions in Annapolis. He said last month he followed ethics rules and regulations. He said he would cooperate with the committee.